Long-term outcomes of osilodrostat in Cushing's disease: LINC 3 study extension.

Maria FleseriuJohn Newell-PriceRosario PivonelloAkira ShimatsuRichard J AuchusCarla ScaroniZhanna BelayaRichard A FeeldersGreisa VilaGhislaine HoudeRama WaliaMiguel IzquierdoMichael RoughtonAlberto M PedroncelliBeverly M K Biller

Published in: European journal of endocrinology (2022)

Data from this large, multicentre trial show that long-term treatment with osilodrostat sustains cortisol normalisation alongside clinical benefits in most patients with CD and is well tolerated.

Keyphrases

study protocol
clinical trial
long non coding rna
cell proliferation
electronic health record
phase iii
big data
randomized controlled trial
cross sectional
double blind
nk cells